Skip to main content
Erschienen in: Pediatric Drugs 3/2015

01.06.2015 | Review Article

Management of Retinoblastoma in Children: Current Status

verfasst von: Guillermo Chantada, Paula Schaiquevich

Erschienen in: Pediatric Drugs | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

In recent years, there have been dramatic changes in the management of intraocular retinoblastoma. Intraocular retinoblastoma is a highly curable malignancy and current treatments are aimed to preserve vision while reducing the late effects such as treatment-induced secondary malignancies. The advent of intra-arterial chemotherapy changed the treatment paradigm from systemic treatment with chemotherapy to local treatment, and new questions emerged. While intra-arterial chemotherapy achieved encouraging results, only experience from major referral centers is reported, so its indications, advantages and risks are still to be elucidated. Many factors should be considered when choosing the appropriate conservative therapy. When the disease has extended outside the eye, the chances of cure are significantly lower and treatment should be tailored by the presence of pathology risk factors such as invasion of the choroid, the optic nerve, and the sclera. Adjuvant therapy is decided upon this information. Children with overt extraocular disease are treated with higher dose neoadjuvant therapy followed by delayed enucleation and adjuvant therapy.
Literatur
1.
Zurück zum Zitat Moll AC, Kuik DJ, Bouter LM, et al. Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862–1995. Br J Ophthalmol. 1997;81:559–62.PubMedCentralPubMedCrossRef Moll AC, Kuik DJ, Bouter LM, et al. Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862–1995. Br J Ophthalmol. 1997;81:559–62.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Dean M, Bendfeldt G, Lou H, et al. Increased incidence and disparity of diagnosis of retinoblastoma patients in Guatemala. Cancer Lett. 2014;351:59–63.PubMedCrossRef Dean M, Bendfeldt G, Lou H, et al. Increased incidence and disparity of diagnosis of retinoblastoma patients in Guatemala. Cancer Lett. 2014;351:59–63.PubMedCrossRef
3.
Zurück zum Zitat Lanier AP, Holck P, Ehrsam Day G, Key C. Childhood cancer among Alaska Natives. Pediatrics. 2003;112:e396.PubMedCrossRef Lanier AP, Holck P, Ehrsam Day G, Key C. Childhood cancer among Alaska Natives. Pediatrics. 2003;112:e396.PubMedCrossRef
4.
Zurück zum Zitat Amozorrutia-Alegria V, Bravo-Ortiz JC, Vazquez-Viveros J, et al. Epidemiological characteristics of retinoblastoma in children attending the Mexican Social Security Institute in Mexico City, 1990–94. Paediatr Perinat Epidemiol. 2002;16:370–4.PubMedCrossRef Amozorrutia-Alegria V, Bravo-Ortiz JC, Vazquez-Viveros J, et al. Epidemiological characteristics of retinoblastoma in children attending the Mexican Social Security Institute in Mexico City, 1990–94. Paediatr Perinat Epidemiol. 2002;16:370–4.PubMedCrossRef
5.
Zurück zum Zitat Moreno F, Sinaki B, Fandino A, Dussel V, Orellana L, Chantada G. A population-based study of retinoblastoma incidence and survival in Argentine children. Pediatr Blood Cancer. 2014;61:1610–5.PubMedCrossRef Moreno F, Sinaki B, Fandino A, Dussel V, Orellana L, Chantada G. A population-based study of retinoblastoma incidence and survival in Argentine children. Pediatr Blood Cancer. 2014;61:1610–5.PubMedCrossRef
6.
Zurück zum Zitat Orjuela MA, Titievsky L, Liu X, et al. Fruit and vegetable intake during pregnancy and risk for development of sporadic retinoblastoma. Cancer Epidemiol Biomarkers Prev. 2005;14:1433–40.PubMedCrossRef Orjuela MA, Titievsky L, Liu X, et al. Fruit and vegetable intake during pregnancy and risk for development of sporadic retinoblastoma. Cancer Epidemiol Biomarkers Prev. 2005;14:1433–40.PubMedCrossRef
7.
Zurück zum Zitat Palazzi MA, Yunes JA, Cardinalli IA, et al. Detection of oncogenic human papillomavirus in sporadic retinoblastoma. Acta Ophthalmol Scand. 2003;81:396–8.PubMedCrossRef Palazzi MA, Yunes JA, Cardinalli IA, et al. Detection of oncogenic human papillomavirus in sporadic retinoblastoma. Acta Ophthalmol Scand. 2003;81:396–8.PubMedCrossRef
8.
Zurück zum Zitat Antoneli CB, Ribeiro KB, Sredni ST, et al. Low prevalence of HPV in Brazilian children with retinoblastoma. J Med Virol. 2011;83:115–8.PubMedCrossRef Antoneli CB, Ribeiro KB, Sredni ST, et al. Low prevalence of HPV in Brazilian children with retinoblastoma. J Med Virol. 2011;83:115–8.PubMedCrossRef
9.
Zurück zum Zitat Marees T, Dommering CJ, Imhof SM, et al. Incidence of retinoblastoma in Dutch children conceived by IVF: an expanded study. Hum Reprod. 2009;24:3220–4.PubMedCrossRef Marees T, Dommering CJ, Imhof SM, et al. Incidence of retinoblastoma in Dutch children conceived by IVF: an expanded study. Hum Reprod. 2009;24:3220–4.PubMedCrossRef
10.
Zurück zum Zitat Foix-L’Helias L, Aerts I, Marchand L, et al. Are children born after infertility treatment at increased risk of retinoblastoma? Hum Reprod. 2012;27:2186–92.PubMedCrossRef Foix-L’Helias L, Aerts I, Marchand L, et al. Are children born after infertility treatment at increased risk of retinoblastoma? Hum Reprod. 2012;27:2186–92.PubMedCrossRef
11.
Zurück zum Zitat Xu K, Rosenwaks Z, Beaverson K, Cholst I, Veeck L, Abramson DH. Preimplantation genetic diagnosis for retinoblastoma: the first reported liveborn. Am J Ophthalmol. 2004;137:18–23.PubMedCrossRef Xu K, Rosenwaks Z, Beaverson K, Cholst I, Veeck L, Abramson DH. Preimplantation genetic diagnosis for retinoblastoma: the first reported liveborn. Am J Ophthalmol. 2004;137:18–23.PubMedCrossRef
12.
Zurück zum Zitat Kleinerman RA, Yu CL, Little MP, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol. 2012;30:950–7.PubMedCentralPubMedCrossRef Kleinerman RA, Yu CL, Little MP, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol. 2012;30:950–7.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Marees T, van Leeuwen FE, de Boer MR, Imhof SM, Ringens PJ, Moll AC. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer. 2009;45:3245–53.PubMedCrossRef Marees T, van Leeuwen FE, de Boer MR, Imhof SM, Ringens PJ, Moll AC. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer. 2009;45:3245–53.PubMedCrossRef
14.
Zurück zum Zitat Moll AC, Imhof SM, Schouten-Van Meeteren AY, Kuik DJ, Hofman P, Boers M. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997: is there an age effect on radiation-related risk? Ophthalmology. 2001;108:1109–14.PubMedCrossRef Moll AC, Imhof SM, Schouten-Van Meeteren AY, Kuik DJ, Hofman P, Boers M. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997: is there an age effect on radiation-related risk? Ophthalmology. 2001;108:1109–14.PubMedCrossRef
15.
Zurück zum Zitat Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd NW 3rd. Presenting signs of retinoblastoma. J Pediatr. 1998;132:505–8.PubMedCrossRef Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd NW 3rd. Presenting signs of retinoblastoma. J Pediatr. 1998;132:505–8.PubMedCrossRef
16.
Zurück zum Zitat Kaimbo WK, Mvitu MM, Missotten L. Presenting signs of retinoblastoma in Congolese patients. Bull Soc Belge Ophtalmol. 2002;282:37–41. Kaimbo WK, Mvitu MM, Missotten L. Presenting signs of retinoblastoma in Congolese patients. Bull Soc Belge Ophtalmol. 2002;282:37–41.
17.
Zurück zum Zitat Parulekar MV. Retinoblastoma—current treatment and future direction. Early Hum Dev. 2010;86:619–25.PubMedCrossRef Parulekar MV. Retinoblastoma—current treatment and future direction. Early Hum Dev. 2010;86:619–25.PubMedCrossRef
18.
Zurück zum Zitat Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol. Clin. North Am. 2005;18:41–53, viii. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol. Clin. North Am. 2005;18:41–53, viii.
19.
Zurück zum Zitat Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829–37.PubMed Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829–37.PubMed
20.
Zurück zum Zitat Turaka K, Shields CL, Meadows AT, Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer. 2012;59:121–5.PubMedCrossRef Turaka K, Shields CL, Meadows AT, Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer. 2012;59:121–5.PubMedCrossRef
22.
Zurück zum Zitat Sitorus RS, Moll AC, Suhardjono S, et al. The effect of therapy refusal against medical advice in retinoblastoma patients in a setting where treatment delays are common. Ophthalmic Genet. 2009;30:31–6.PubMedCrossRef Sitorus RS, Moll AC, Suhardjono S, et al. The effect of therapy refusal against medical advice in retinoblastoma patients in a setting where treatment delays are common. Ophthalmic Genet. 2009;30:31–6.PubMedCrossRef
23.
Zurück zum Zitat Canturk S, Qaddoumi I, Khetan V, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol. 2010;94:1432–6.PubMedCrossRef Canturk S, Qaddoumi I, Khetan V, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol. 2010;94:1432–6.PubMedCrossRef
24.
Zurück zum Zitat Gupta R, Vemuganti GK, Reddy VA, Honavar SG. Histopathologic risk factors in retinoblastoma in India. Arch Pathol Lab Med. 2009;133:1210–4.PubMed Gupta R, Vemuganti GK, Reddy VA, Honavar SG. Histopathologic risk factors in retinoblastoma in India. Arch Pathol Lab Med. 2009;133:1210–4.PubMed
25.
Zurück zum Zitat Chantada GL, Dunkel IJ, de Davila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069–73.PubMedCentralPubMedCrossRef Chantada GL, Dunkel IJ, de Davila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88:1069–73.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat de Graaf P, Goricke S, Rodjan F, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol. 2012;42:2–14.PubMedCentralPubMedCrossRef de Graaf P, Goricke S, Rodjan F, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol. 2012;42:2–14.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Kashyap S, Meel R, Pushker N, et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr Blood Cancer. 2012;58:356–61.PubMedCrossRef Kashyap S, Meel R, Pushker N, et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr Blood Cancer. 2012;58:356–61.PubMedCrossRef
28.
Zurück zum Zitat Chantada GL, Gonzalez A, Fandino A, et al. Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma. J Pediatr Hematol Oncol. 2009;31:325–9.PubMedCrossRef Chantada GL, Gonzalez A, Fandino A, et al. Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma. J Pediatr Hematol Oncol. 2009;31:325–9.PubMedCrossRef
29.
Zurück zum Zitat Kaliki S, Shields CL, Rojanaporn D, et al. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology. 2013;120:997–1003.PubMedCrossRef Kaliki S, Shields CL, Rojanaporn D, et al. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology. 2013;120:997–1003.PubMedCrossRef
30.
Zurück zum Zitat Wilson MW, Qaddoumi I, Billups C, Haik BG, Rodriguez-Galindo C. A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma. Br J Ophthalmol. 2011;95:553–8.PubMedCrossRef Wilson MW, Qaddoumi I, Billups C, Haik BG, Rodriguez-Galindo C. A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma. Br J Ophthalmol. 2011;95:553–8.PubMedCrossRef
31.
Zurück zum Zitat Laurent VE, Sampor C, Solernou V, et al. Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. Eur J Cancer. 2013;49:2892–9.PubMedCrossRef Laurent VE, Sampor C, Solernou V, et al. Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. Eur J Cancer. 2013;49:2892–9.PubMedCrossRef
32.
Zurück zum Zitat McCormick B, Ellsworth R, Abramson D, LoSasso T, Grabowski E. Results of external beam radiation for children with retinoblastoma: a comparison of two techniques. J Pediatr Ophthalmol Strabismus. 1989;26:239–43.PubMed McCormick B, Ellsworth R, Abramson D, LoSasso T, Grabowski E. Results of external beam radiation for children with retinoblastoma: a comparison of two techniques. J Pediatr Ophthalmol Strabismus. 1989;26:239–43.PubMed
33.
Zurück zum Zitat Levin MH, Gombos DS, O’Brien JM. Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial? Arch Ophthalmol. 2011;129:1487–9.PubMedCrossRef Levin MH, Gombos DS, O’Brien JM. Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial? Arch Ophthalmol. 2011;129:1487–9.PubMedCrossRef
34.
Zurück zum Zitat Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081–7.PubMedCrossRef Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081–7.PubMedCrossRef
35.
Zurück zum Zitat Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129:732–7.PubMedCrossRef Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129:732–7.PubMedCrossRef
36.
Zurück zum Zitat Lee V, Hungerford JL, Bunce C, Ahmed F, Kingston JE, Plowman PN. Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol. 2003;87:1374–80.PubMedCentralPubMedCrossRef Lee V, Hungerford JL, Bunce C, Ahmed F, Kingston JE, Plowman PN. Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol. 2003;87:1374–80.PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Grigorovski N, Lucena E, Mattosinho C, et al. Use of intra-arterial chemotherapy for retinoblastoma: results of a survey. Int J Ophthalmol. 2014;7:726–30.PubMedCentralPubMed Grigorovski N, Lucena E, Mattosinho C, et al. Use of intra-arterial chemotherapy for retinoblastoma: results of a survey. Int J Ophthalmol. 2014;7:726–30.PubMedCentralPubMed
38.
Zurück zum Zitat Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond). 2013;27:253–64.CrossRef Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond). 2013;27:253–64.CrossRef
39.
40.
Zurück zum Zitat Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203–12.PubMedCrossRef Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203–12.PubMedCrossRef
41.
Zurück zum Zitat Willard VW, Qaddoumi I, Chen S, et al. Developmental and adaptive functioning in children with retinoblastoma: a longitudinal investigation. J Clin Oncol. 2014;32:2788–93.PubMedCrossRef Willard VW, Qaddoumi I, Chen S, et al. Developmental and adaptive functioning in children with retinoblastoma: a longitudinal investigation. J Clin Oncol. 2014;32:2788–93.PubMedCrossRef
42.
Zurück zum Zitat van Dijk J, Imhof SM, Moll AC, et al. Quality of life of adult retinoblastoma survivors in The Netherlands. Health Qual Life Outcomes. 2007;5:30.PubMedCentralPubMedCrossRef van Dijk J, Imhof SM, Moll AC, et al. Quality of life of adult retinoblastoma survivors in The Netherlands. Health Qual Life Outcomes. 2007;5:30.PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Eagle RC Jr, Shields CL, Bianciotto C, Jabbour P, Shields JA. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol. 2011;129:1416–21.PubMedCrossRef Eagle RC Jr, Shields CL, Bianciotto C, Jabbour P, Shields JA. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol. 2011;129:1416–21.PubMedCrossRef
44.
Zurück zum Zitat Bosaleh A, Sampor C, Solernou V, et al. Outcome of children with retinoblastoma and isolated choroidal invasion. Arch Ophthalmol. 2012;130:724–9.PubMedCrossRef Bosaleh A, Sampor C, Solernou V, et al. Outcome of children with retinoblastoma and isolated choroidal invasion. Arch Ophthalmol. 2012;130:724–9.PubMedCrossRef
45.
Zurück zum Zitat Olteanu C, Dimaras H. Enucleation refusal for retinoblastoma: a global study. Ophthalmic Genet. 2014;31:1–7.CrossRef Olteanu C, Dimaras H. Enucleation refusal for retinoblastoma: a global study. Ophthalmic Genet. 2014;31:1–7.CrossRef
46.
Zurück zum Zitat Chantada GL, Qaddoumi I, Canturk S, et al. Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer. 2011;56:341–8.PubMedCrossRef Chantada GL, Qaddoumi I, Canturk S, et al. Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer. 2011;56:341–8.PubMedCrossRef
47.
Zurück zum Zitat Zhao J, Dimaras H, Massey C, et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol. 2011;29:845–51.PubMedCrossRef Zhao J, Dimaras H, Massey C, et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol. 2011;29:845–51.PubMedCrossRef
48.
Zurück zum Zitat Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1339–43.PubMedCrossRef Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1339–43.PubMedCrossRef
49.
Zurück zum Zitat Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.PubMedCrossRef Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.PubMedCrossRef
50.
Zurück zum Zitat Naseripour M, Nazari H, Bakhtiari P, Modarres-zadeh M, Vosough P, Ausari M. Retinoblastoma in Iran: outcomes in terms of patients’ survival and globe survival. Br J Ophthalmol. 2009;93:28–32.PubMedCrossRef Naseripour M, Nazari H, Bakhtiari P, Modarres-zadeh M, Vosough P, Ausari M. Retinoblastoma in Iran: outcomes in terms of patients’ survival and globe survival. Br J Ophthalmol. 2009;93:28–32.PubMedCrossRef
51.
Zurück zum Zitat Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol. 2011;129:1407–15.PubMedCrossRef Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol. 2011;129:1407–15.PubMedCrossRef
52.
Zurück zum Zitat Dunkel IJ, Shi W, Salvaggio K, et al. Risk factors for severe neutropenia following intra-arterial chemotherapy for intra-ocular retinoblastoma. PLoS One. 2014;9:e108692.PubMedCentralPubMedCrossRef Dunkel IJ, Shi W, Salvaggio K, et al. Risk factors for severe neutropenia following intra-arterial chemotherapy for intra-ocular retinoblastoma. PLoS One. 2014;9:e108692.PubMedCentralPubMedCrossRef
53.
Zurück zum Zitat Chantada GL, Fandino AC, Schvartzman E, Raslawski E, Schaiquevich P, Manzitti J. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina. Pediatr Blood Cancer. 2014;61:821–6.PubMedCrossRef Chantada GL, Fandino AC, Schvartzman E, Raslawski E, Schaiquevich P, Manzitti J. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina. Pediatr Blood Cancer. 2014;61:821–6.PubMedCrossRef
54.
Zurück zum Zitat Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114:1378–83.PubMedCrossRef Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114:1378–83.PubMedCrossRef
55.
56.
Zurück zum Zitat Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52:637–43.PubMedCrossRef Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52:637–43.PubMedCrossRef
57.
Zurück zum Zitat Shields CL, Shields JA, Meadows AT. Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma. J Clin Oncol. 2000;18:236–7.PubMed Shields CL, Shields JA, Meadows AT. Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma. J Clin Oncol. 2000;18:236–7.PubMed
58.
Zurück zum Zitat Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer. 2012;118:5663–70.PubMedCentralPubMedCrossRef Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer. 2012;118:5663–70.PubMedCentralPubMedCrossRef
59.
Zurück zum Zitat Lumbroso L, Doz F, Urbieta M, et al. Chemothermotherapy in the management of retinoblastoma. Ophthalmology. 2002;109:1130–6.PubMedCrossRef Lumbroso L, Doz F, Urbieta M, et al. Chemothermotherapy in the management of retinoblastoma. Ophthalmology. 2002;109:1130–6.PubMedCrossRef
60.
Zurück zum Zitat Greenwald MJ, Strauss LC. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1997;3:491–2.PubMed Greenwald MJ, Strauss LC. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1997;3:491–2.PubMed
61.
Zurück zum Zitat Berry JL, Jubran R, Kim JW, et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2013;60:688–93.PubMedCrossRef Berry JL, Jubran R, Kim JW, et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2013;60:688–93.PubMedCrossRef
62.
Zurück zum Zitat Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398–404, 404 e1. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398–404, 404 e1.
63.
Zurück zum Zitat Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol. 2004;9:1–6.PubMedCrossRef Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol. 2004;9:1–6.PubMedCrossRef
64.
Zurück zum Zitat Schaiquevich P, Buitrago E, Taich P, et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012;53:4205–12.PubMedCrossRef Schaiquevich P, Buitrago E, Taich P, et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012;53:4205–12.PubMedCrossRef
65.
Zurück zum Zitat Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011;31:566–73.PubMedCrossRef Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011;31:566–73.PubMedCrossRef
66.
Zurück zum Zitat Gobin YP, Rosenstein LM, Marr BP, Brodie SE, Abramson DH. Radiation exposure during intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol. 2012;130:403–4 (author reply 4–5).PubMedCrossRef Gobin YP, Rosenstein LM, Marr BP, Brodie SE, Abramson DH. Radiation exposure during intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol. 2012;130:403–4 (author reply 4–5).PubMedCrossRef
67.
Zurück zum Zitat Francis JH, Gobin YP, Nagiel A, et al. Thrombophilia in patients with retinoblastoma receiving ophthalmic artery chemosurgery. Arch Ophthalmol. 2012;130:1605–8.PubMedCrossRef Francis JH, Gobin YP, Nagiel A, et al. Thrombophilia in patients with retinoblastoma receiving ophthalmic artery chemosurgery. Arch Ophthalmol. 2012;130:1605–8.PubMedCrossRef
68.
Zurück zum Zitat Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:1453–60.PubMedCrossRef Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:1453–60.PubMedCrossRef
69.
Zurück zum Zitat Venturi C, Bracco S, Cerase A, et al. Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments. Acta Ophthalmol. 2013;91:335–42.PubMedCrossRef Venturi C, Bracco S, Cerase A, et al. Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments. Acta Ophthalmol. 2013;91:335–42.PubMedCrossRef
70.
Zurück zum Zitat Francis JH, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, Abramson DH. Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma. Br J Ophthalmol. 2012;96:1270–1.PubMedCrossRef Francis JH, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, Abramson DH. Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma. Br J Ophthalmol. 2012;96:1270–1.PubMedCrossRef
71.
Zurück zum Zitat Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH. Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol. 2012;96:1300–3.PubMedCrossRef Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH. Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol. 2012;96:1300–3.PubMedCrossRef
72.
Zurück zum Zitat Palioura S, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, Abramson DH. Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50 %) retinal detachment. Pediatr Blood Cancer. 2012;59:859–64.PubMedCrossRef Palioura S, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, Abramson DH. Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50 %) retinal detachment. Pediatr Blood Cancer. 2012;59:859–64.PubMedCrossRef
73.
Zurück zum Zitat Abramson DH, Marr BP, Brodie SE, Dunkel I, Palioura S, Gobin YP. Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS One. 2012;7:e34120.PubMedCentralPubMedCrossRef Abramson DH, Marr BP, Brodie SE, Dunkel I, Palioura S, Gobin YP. Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS One. 2012;7:e34120.PubMedCentralPubMedCrossRef
74.
Zurück zum Zitat Biswas J, Das D, Krishnakumar S, Shanmugam MP. Histopathologic analysis of 232 eyes with retinoblastoma conducted in an Indian tertiary-care ophthalmic center. J Pediatr Ophthalmol Strabismus. 2003;40:265–7.PubMed Biswas J, Das D, Krishnakumar S, Shanmugam MP. Histopathologic analysis of 232 eyes with retinoblastoma conducted in an Indian tertiary-care ophthalmic center. J Pediatr Ophthalmol Strabismus. 2003;40:265–7.PubMed
75.
Zurück zum Zitat Chan MP, Hungerford JL, Kingston JE, Plowman PN. Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br J Ophthalmol. 2009;93:891–4.PubMedCrossRef Chan MP, Hungerford JL, Kingston JE, Plowman PN. Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br J Ophthalmol. 2009;93:891–4.PubMedCrossRef
76.
Zurück zum Zitat Chantada GL, Dunkel IJ, Antoneli CB, et al. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer. 2007;49:256–60.PubMedCrossRef Chantada GL, Dunkel IJ, Antoneli CB, et al. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer. 2007;49:256–60.PubMedCrossRef
77.
Zurück zum Zitat Schaiquevich P, Ceciliano A, Millan N, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer. 2013;60:766–70.PubMedCrossRef Schaiquevich P, Ceciliano A, Millan N, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer. 2013;60:766–70.PubMedCrossRef
78.
Zurück zum Zitat Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132:319–25.PubMedCrossRef Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132:319–25.PubMedCrossRef
79.
Zurück zum Zitat Munier FL, Gaillard MC, Balmer A, Beck-Popovic M. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: recent advances and perspectives. Saudi J Ophthalmol. 2013;27:147–50.PubMedCentralPubMedCrossRef Munier FL, Gaillard MC, Balmer A, Beck-Popovic M. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: recent advances and perspectives. Saudi J Ophthalmol. 2013;27:147–50.PubMedCentralPubMedCrossRef
80.
81.
Zurück zum Zitat Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33:601–7.PubMedCrossRef Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33:601–7.PubMedCrossRef
82.
Zurück zum Zitat Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 2014;132:936–41.PubMedCrossRef Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 2014;132:936–41.PubMedCrossRef
83.
Zurück zum Zitat Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121:1810–7.PubMedCrossRef Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121:1810–7.PubMedCrossRef
84.
Zurück zum Zitat Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133:1199–202.PubMed Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133:1199–202.PubMed
85.
Zurück zum Zitat Leal-Leal CA, Rivera-Luna R, Flores-Rojo M, Juarez-Echenique JC, Ordaz JC, Amador-Zarco J. Survival in extra-orbital metastatic retinoblastoma: treatment results. Clin Transl Oncol. 2006;8:39–44.PubMedCrossRef Leal-Leal CA, Rivera-Luna R, Flores-Rojo M, Juarez-Echenique JC, Ordaz JC, Amador-Zarco J. Survival in extra-orbital metastatic retinoblastoma: treatment results. Clin Transl Oncol. 2006;8:39–44.PubMedCrossRef
86.
Zurück zum Zitat Baroni LV, Sampor C, Fandino A, et al. Anterior segment invasion in retinoblastoma: is it a risk factor for extraocular relapse? J Pediatr Hematol Oncol. 2014;36:509–12.CrossRef Baroni LV, Sampor C, Fandino A, et al. Anterior segment invasion in retinoblastoma: is it a risk factor for extraocular relapse? J Pediatr Hematol Oncol. 2014;36:509–12.CrossRef
87.
Zurück zum Zitat Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1996;77:1206–13.PubMedCrossRef Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1996;77:1206–13.PubMedCrossRef
88.
Zurück zum Zitat Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31:1458–63.PubMedCrossRef Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol. 2013;31:1458–63.PubMedCrossRef
89.
Zurück zum Zitat Chantada GL, Guitter MR, Fandino AC, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer. 2009;52:218–22.PubMedCrossRef Chantada GL, Guitter MR, Fandino AC, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer. 2009;52:218–22.PubMedCrossRef
90.
Zurück zum Zitat Chantada GL, Sampor C, Bosaleh A, Solernou V, Fandino A, de Davila MT. Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. JAMA Ophthalmol. 2013;131:1127–34.PubMedCrossRef Chantada GL, Sampor C, Bosaleh A, Solernou V, Fandino A, de Davila MT. Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. JAMA Ophthalmol. 2013;131:1127–34.PubMedCrossRef
91.
Zurück zum Zitat Shields CL, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77:544–8.PubMedCentralPubMedCrossRef Shields CL, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77:544–8.PubMedCentralPubMedCrossRef
92.
Zurück zum Zitat Kaliki S, Shields CL, Shah SU, Eagle RC Jr, Shields JA, Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129:1422–7.PubMedCrossRef Kaliki S, Shields CL, Shah SU, Eagle RC Jr, Shields JA, Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129:1422–7.PubMedCrossRef
93.
Zurück zum Zitat Chantada GL, Fandino AC, Guitter MR, et al. Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer. 2010;55:60–6.PubMed Chantada GL, Fandino AC, Guitter MR, et al. Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer. 2010;55:60–6.PubMed
94.
Zurück zum Zitat Friedman DN, Sklar CA, Oeffinger KC, et al. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr Blood Cancer. 2013;60:694–9.PubMedCrossRef Friedman DN, Sklar CA, Oeffinger KC, et al. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr Blood Cancer. 2013;60:694–9.PubMedCrossRef
95.
Zurück zum Zitat Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology. 1989;96:217–22.PubMedCrossRef Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology. 1989;96:217–22.PubMedCrossRef
96.
Zurück zum Zitat Sullivan EM, Wilson MW, Billups CA, et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol. 2014;36:e335–40.PubMedCrossRef Sullivan EM, Wilson MW, Billups CA, et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol. 2014;36:e335–40.PubMedCrossRef
97.
Zurück zum Zitat Chantada GL, Casco F, Fandino AC, et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology. 2007;114:2083–9.PubMedCrossRef Chantada GL, Casco F, Fandino AC, et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology. 2007;114:2083–9.PubMedCrossRef
98.
Zurück zum Zitat Cuenca A, Giron F, Castro D, et al. Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol. 2009;127:1006–10.PubMedCrossRef Cuenca A, Giron F, Castro D, et al. Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol. 2009;127:1006–10.PubMedCrossRef
99.
Zurück zum Zitat Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29:700–4.PubMedCrossRef Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol. 2007;29:700–4.PubMedCrossRef
100.
101.
Zurück zum Zitat Brisse HJ, de Graaf P, Galluzzi P, et al. Assessment of early-stage optic nerve invasion in retinoblastoma using high-resolution 1.5 Tesla MRI with surface coils: a multicentre, prospective accuracy study with histopathological correlation. Eur Radiol. 2014. doi:10.1007/s00330-014-3514-1. Brisse HJ, de Graaf P, Galluzzi P, et al. Assessment of early-stage optic nerve invasion in retinoblastoma using high-resolution 1.5 Tesla MRI with surface coils: a multicentre, prospective accuracy study with histopathological correlation. Eur Radiol. 2014. doi:10.​1007/​s00330-014-3514-1.
102.
Zurück zum Zitat Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma. The experience of a single institution with 33 patients. Cancer. 1994;74:722–32.PubMedCrossRef Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma. The experience of a single institution with 33 patients. Cancer. 1994;74:722–32.PubMedCrossRef
103.
Zurück zum Zitat Ali MJ, Reddy VA, Honavar SG, Naik M. Orbital retinoblastoma: where do we go from here? J Cancer Res Ther. 2011;7:11–4.PubMedCrossRef Ali MJ, Reddy VA, Honavar SG, Naik M. Orbital retinoblastoma: where do we go from here? J Cancer Res Ther. 2011;7:11–4.PubMedCrossRef
104.
Zurück zum Zitat Radhakrishnan V, Sharma S, Vishnubhatla S, Bakhshi S. MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). Br J Ophthalmol. 2013;97:52–8.PubMedCrossRef Radhakrishnan V, Sharma S, Vishnubhatla S, Bakhshi S. MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). Br J Ophthalmol. 2013;97:52–8.PubMedCrossRef
105.
Zurück zum Zitat Dunkel IJ, Khakoo Y, Kernan NA, et al. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer. 2010;55:55–9.PubMed Dunkel IJ, Khakoo Y, Kernan NA, et al. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer. 2010;55:55–9.PubMed
106.
Zurück zum Zitat Palma J, Sasso DF, Dufort G, et al. Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant. 2012;47:522–7.PubMedCrossRef Palma J, Sasso DF, Dufort G, et al. Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant. 2012;47:522–7.PubMedCrossRef
107.
Zurück zum Zitat Dunkel IJ, Chan HS, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010;55:149–52.PubMed Dunkel IJ, Chan HS, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010;55:149–52.PubMed
108.
Zurück zum Zitat Dimaras H, Heon E, Budning A, et al. Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation. Ophthalmic Genet. 2009;30:121–6.PubMedCrossRef Dimaras H, Heon E, Budning A, et al. Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation. Ophthalmic Genet. 2009;30:121–6.PubMedCrossRef
109.
110.
Zurück zum Zitat Shields CL, Honavar S, Shields JA, Demirci H, Meadows AT. Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology. 2000;107:2250–5.PubMedCrossRef Shields CL, Honavar S, Shields JA, Demirci H, Meadows AT. Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology. 2000;107:2250–5.PubMedCrossRef
111.
Zurück zum Zitat Chantada G, Leal-Leal C, Brisse H, et al. Is it pre-enucleation chemotherapy or delayed enucleation of severely involved eyes with intraocular retinoblastoma that risks extraocular dissemination and death? J Clin Oncol. 2011;29:3333–4 (author reply 5–6).PubMedCrossRef Chantada G, Leal-Leal C, Brisse H, et al. Is it pre-enucleation chemotherapy or delayed enucleation of severely involved eyes with intraocular retinoblastoma that risks extraocular dissemination and death? J Clin Oncol. 2011;29:3333–4 (author reply 5–6).PubMedCrossRef
112.
Zurück zum Zitat Schaiquevich P, Carcaboso AM, Buitrago E, et al. Ocular pharmacology of topotecan and its activity in retinoblastoma. Retina. 2014;34:1719–27.PubMedCrossRef Schaiquevich P, Carcaboso AM, Buitrago E, et al. Ocular pharmacology of topotecan and its activity in retinoblastoma. Retina. 2014;34:1719–27.PubMedCrossRef
113.
Zurück zum Zitat Hayden BC, Jockovich ME, Murray TG, et al. Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004;45:3644–9.PubMedCrossRef Hayden BC, Jockovich ME, Murray TG, et al. Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004;45:3644–9.PubMedCrossRef
114.
Zurück zum Zitat Requejo F, Sierre S, Marelli J, et al. Ophtalmic artery microcatheterization for research purposes in pigs. A technical note. J Invest Surg. 2014;27:291–3.PubMedCrossRef Requejo F, Sierre S, Marelli J, et al. Ophtalmic artery microcatheterization for research purposes in pigs. A technical note. J Invest Surg. 2014;27:291–3.PubMedCrossRef
115.
Zurück zum Zitat Steinle JJ, Zhang Q, Thompson KE, et al. Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis. Invest Ophthalmol Vis Sci. 2012;53:2439–45.PubMedCentralPubMedCrossRef Steinle JJ, Zhang Q, Thompson KE, et al. Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis. Invest Ophthalmol Vis Sci. 2012;53:2439–45.PubMedCentralPubMedCrossRef
116.
Zurück zum Zitat Tse BC, Steinle JJ, Johnson D, Haik BG, Wilson MW. Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings. JAMA Ophthalmol. 2013;131:903–11.PubMedCentralPubMedCrossRef Tse BC, Steinle JJ, Johnson D, Haik BG, Wilson MW. Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings. JAMA Ophthalmol. 2013;131:903–11.PubMedCentralPubMedCrossRef
118.
Zurück zum Zitat Pontes de Carvalho RA, Krausse ML, Murphree AL, Schmitt EE, Campochiaro PA, Maumenee IH. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci. 2006;47:4532–9.PubMedCrossRef Pontes de Carvalho RA, Krausse ML, Murphree AL, Schmitt EE, Campochiaro PA, Maumenee IH. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci. 2006;47:4532–9.PubMedCrossRef
119.
Zurück zum Zitat Martin NE, Kim JW, Abramson DH. Fibrin sealant for retinoblastoma: where are we? J Ocul Pharmacol Ther. 2008;24:433–8.PubMedCrossRef Martin NE, Kim JW, Abramson DH. Fibrin sealant for retinoblastoma: where are we? J Ocul Pharmacol Ther. 2008;24:433–8.PubMedCrossRef
120.
Zurück zum Zitat Mallipatna AC, Dimaras H, Chan HS, Heon E, Gallie BL. Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol. 2011;129:738–45.PubMedCrossRef Mallipatna AC, Dimaras H, Chan HS, Heon E, Gallie BL. Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol. 2011;129:738–45.PubMedCrossRef
121.
Zurück zum Zitat Houston SK, Pina Y, Murray TG, et al. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Clin Ophthalmol. 2011;5:129–37.PubMedCentralPubMed Houston SK, Pina Y, Murray TG, et al. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Clin Ophthalmol. 2011;5:129–37.PubMedCentralPubMed
122.
Zurück zum Zitat Boutrid H, Jockovich ME, Murray TG, et al. Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:2799–805.PubMedCrossRef Boutrid H, Jockovich ME, Murray TG, et al. Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:2799–805.PubMedCrossRef
123.
Zurück zum Zitat Brennan RC, Federico S, Bradley C, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res. 2011;71:4205–13.PubMedCentralPubMedCrossRef Brennan RC, Federico S, Bradley C, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res. 2011;71:4205–13.PubMedCentralPubMedCrossRef
124.
Zurück zum Zitat Laurie NA, Shih CS, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets. 2007;7:689–95.PubMedCrossRef Laurie NA, Shih CS, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets. 2007;7:689–95.PubMedCrossRef
125.
Zurück zum Zitat Zhang F, Tagen M, Throm S, et al. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos Biol Fate Chem. 2011;39:15–21.PubMedCentralPubMedCrossRef Zhang F, Tagen M, Throm S, et al. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos Biol Fate Chem. 2011;39:15–21.PubMedCentralPubMedCrossRef
126.
Zurück zum Zitat Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481:329–34.PubMedCentralPubMed Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481:329–34.PubMedCentralPubMed
127.
Zurück zum Zitat Pritchard EM, Stewart E, Zhu F, et al. Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor R406 after ocular delivery for retinoblastoma. Pharm Res. 2014;31:3060–72.PubMedCentralPubMedCrossRef Pritchard EM, Stewart E, Zhu F, et al. Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor R406 after ocular delivery for retinoblastoma. Pharm Res. 2014;31:3060–72.PubMedCentralPubMedCrossRef
128.
Zurück zum Zitat Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14:327–34.PubMedCrossRef Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14:327–34.PubMedCrossRef
129.
Zurück zum Zitat Kapatai G, Brundler MA, Jenkinson H, et al. Gene expression profiling identifies different sub-types of retinoblastoma. Br J Cancer. 2013;109:512–25.PubMedCentralPubMedCrossRef Kapatai G, Brundler MA, Jenkinson H, et al. Gene expression profiling identifies different sub-types of retinoblastoma. Br J Cancer. 2013;109:512–25.PubMedCentralPubMedCrossRef
130.
Zurück zum Zitat Dimaras H, Rushlow D, Halliday W, et al. Using RB1 mutations to assess minimal residual disease in metastatic retinoblastoma. Transl Res. 2010;156:91–7.PubMedCrossRef Dimaras H, Rushlow D, Halliday W, et al. Using RB1 mutations to assess minimal residual disease in metastatic retinoblastoma. Transl Res. 2010;156:91–7.PubMedCrossRef
131.
Zurück zum Zitat de Graaf P, Pouwels PJ, Rodjan F, et al. Single-shot turbo spin-echo diffusion-weighted imaging for retinoblastoma: initial experience. AJNR Am J Neuroradiol. 2012;33:110–8.PubMedCrossRef de Graaf P, Pouwels PJ, Rodjan F, et al. Single-shot turbo spin-echo diffusion-weighted imaging for retinoblastoma: initial experience. AJNR Am J Neuroradiol. 2012;33:110–8.PubMedCrossRef
Metadaten
Titel
Management of Retinoblastoma in Children: Current Status
verfasst von
Guillermo Chantada
Paula Schaiquevich
Publikationsdatum
01.06.2015
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 3/2015
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-015-0121-9

Weitere Artikel der Ausgabe 3/2015

Pediatric Drugs 3/2015 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.